Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Score
Protagonist Therapeutics, Inc. price target
| PTGX | |
|---|---|
| Low | $165.00 |
| Average | $177.25 |
| High | $190.00 |
| Upside vs current price | +35.4% |
The average target of $177.25 is +35.4% versus the current PTGX price of $130.95.
Protagonist Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 3 |
| Buy | 11 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
14 analysts cover PTGX.
Protagonist Therapeutics, Inc. EPS and revenue estimates
Published annual figures for PTGX on this page are 2026 EPS $4.69, 2027 EPS $-0.39. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $4.69 | $549.62M |
| 2027 | $-0.39 | $204.70M |
Is Protagonist Therapeutics, Inc. a buy or sell?
Of the 14 analysts covering Protagonist Therapeutics, Inc., 14 rate it a buy (3 strong buy and 11 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The PTGX consensus label is Buy, beside 14 buy-side ratings and 0 sell-side ratings.
The average target of $177.25 implies +35.4% versus the current price of $130.95.
The PTGX rating block is 14 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the Protagonist Therapeutics, Inc. forecast
the Protagonist Therapeutics, Inc. has a tight target cluster: $165.00 to $190.00, average $177.25.
The gap from the $130.95 price to the PTGX average is +35.4%.
The PTGX rating mix is lopsided rather than split: 14 of 14 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
The latest PTGX actions do not point one way: 1 up and 0 down.
Month by month, the PTGX average target is higher ($184.00) than the quarterly average ($176.00).
With 14 analysts on PTGX, the average is a small sample.
Protagonist Therapeutics, Inc. forecast questions
What is the PTGX price target?
The published range for PTGX is $165.00 to $190.00, with an average of $177.25. That average is +35.4% versus the current price of $130.95.
Is Protagonist Therapeutics, Inc. a buy or sell?
Of the 14 analysts covering Protagonist Therapeutics, Inc., 14 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, leaving PTGX at 14 buy ratings, 0 holds, and 0 sells.
What is the EPS estimate for Protagonist Therapeutics, Inc.?
Analyst EPS estimates for Protagonist Therapeutics, Inc.: 2026 $4.69, 2027 $-0.39.
What is the revenue estimate for Protagonist Therapeutics, Inc.?
Analyst revenue estimates for Protagonist Therapeutics, Inc.: 2026 $549.62M, 2027 $204.70M.
How many analysts cover PTGX?
14 analysts cover PTGX. Their consensus on PTGX is Buy, across those 14.